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Introduction
Myeloproliferative neoplasms (MPNs) comprise a heterogeneous 
group of malignant clonal hematopoietic diseases including, 
among others, BCR-ABL1–negative polycythemia vera (PV), essen-
tial thrombocythemia (ET), and primary myelofibrosis (PMF), as 
well as BCR-ABL1–positive chronic myelogenous leukemia (CML). 
While the BCR-ABL1 fusion protein results in a constitutively acti-
vated tyrosine kinase activity in CML, BCR-ABL1–negative MPNs 
often harbor mutations in the Janus kinase (JAK)/signal trans-
ducer and activator of transcription (STAT) pathway. Both types of 
genetic alterations lead to abnormal proliferation of myeloid cells 
in the absence of overt signs of morphological dysplasia (1).
Although the role of cytokines and growth factors in normal 
hematopoiesis is widely recognized, their precise contribution to 
MPN pathogenesis is still unclear. In vitro, cells from MPN patients 
are characterized by an intrinsic independence and/or hypersensi-
tivity to growth-factor stimulation and cytokine stimulation (2, 3). 
In CML cells, the BCR-ABL1 protein stimulates constant autocrine 
production of IL-3, IL-6, G-CSF, and TNF (3–5). The long-term 
outcome of CML patients has substantially improved with the use 
of the tyrosine kinase inhibitor imatinib, yet its efficacy may be 
hampered by the action of cytokines (6). The JAK2V617F mutation 
is often found in BCR-ABL1–negative MPNs and similarly results 
in constitutively activated kinase activity, mimicking persistent 
signaling via multiple cytokine pathways. While JAK inhibitors 
have been successful in treating JAK2-mutated MPNs, elimination 
of the mutant clone and resistance may pose an important prob-
lem, and patients with WT JAK2 MPNs are not amenable to this 
therapy (7). The abnormal expression and activity of a number of 
proinflammatory cytokines are associated with BCR-ABL1–nega-
tive MPNs (8), possibly initiating clonal evolution (9) or promot-
ing progression to myelofibrosis (10) and resistance against JAK2 
inhibitors (11). Thus, cytokines and growth factors support the 
aberrant hematopoiesis associated with MPNs and provide mech-
anisms for drug resistance.
While several studies suggest that concomitant inflammation 
supports MPN pathogenesis and development, it remains elusive 
whether inflammation precedes and may thus initiate the mye-
loproliferation. Indeed, previous inflammatory conditions have 
been linked to myeloid malignancies (12). Moreover, recent epi-
demiologic studies have reported an association between MPNs 
and either certain autoimmune diseases (13) or antecedent chronic 
inflammatory conditions of infectious origin (14). Microbe-sensing 
receptors — and TLRs in particular — may initiate such inflamma-
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Given the possible association between certain infections and 
malignant transformation of the myeloid lineage (14), we inves-
tigated the putative role for environmental inflammatory cues in 
the development of dysregulated myeloproliferation in the styx 
model. We followed a genetic strategy to systematically disrupt 
signaling molecules relevant for microbe sensing, focusing on 
TLRs. Because of its pure C57BL/6J background, the styx strain 
appeared particularly suitable for such an approach, in contrast to 
the non–C57BL/6 Inpp5d KO strains generated so far (23–25).
We found that genetic disruption of Myd88, a central protein 
adapter that relays signals from most TLRs, abrogated fatal MPN-
like disease in styx mutants (Figure 1, A and B). Accordingly, styx 
mice lacking IRAK4, a protein directly downstream of MyD88 in 
the signaling cascade, were also rescued from the MPN pheno-
type (Figure 1A). However, single deletion of Tlr2 or Tlr4, critical 
sensors of microbial products derived from commensal bacteria, 
failed to prevent disease progression on the styx background. styx 
Unc93b13d/3d double mutants with impaired endosomal TLR signal-
ing died earlier compared with styx mice, likely from an increased 
susceptibility to opportunistic infections (Supplemental Figure 2A).
We further hypothesized that MPN development may be 
provoked by synergistic signaling via multiple TLRs converging 
toward MyD88 and IRAK4. However, styx mice rederived into a 
germ-free environment, and consequently exposed to a greatly 
reduced quantity of TLR ligands, developed MPN-like disease at 
the same rate and severity as mice kept under specific pathogen–
free (SPF) conditions (Supplemental Figure 2).
TLR signaling triggers host cell responses with production of 
effector cytokines such as TNF. Introduction of a mutation dis-
rupting TNF binding to its receptor significantly extended life-
span but failed to completely rescue styx mice. This reveals a par-
tial contribution of TNF to disease development and associated 
immunopathology in our model (Figure 1A).
In brief, progression of MPN-like disease in styx mutants is 
controlled by signaling through MyD88 and IRAK4, but not TLRs. 
Moreover, the commensal microbiota is not required to induce the 
observed phenotype.
A non-redundant contribution of the IL-33/ST2 pathway to 
MPNs. MyD88 and IRAK4 not only transduce signaling from 
TLRs, but they are also located downstream of the receptors 
for the cytokines IL-1, IL-18, and IL-33. Abrogation of signaling 
through the IL-1 or IL-18 pathways did not limit SHIP-controlled 
myeloproliferation (Figure 1C).
However, styx mice with bi-allelic deficiency in the 
MyD88-dependent IL-33 receptor ST2 were found to be pro-
tected from disease development (Figure 1C), demonstrating that 
signaling from ST2 was necessary to induce MPN-like disease in 
styx mutants.
Dysregulated BM hematopoiesis is a key feature of MPNs 
in humans and is also the primary etiology for the myelopro-
liferative disease accompanying SHIP deficiency (23). We thus 
assessed hematopoietic stem cell (HSC) and myeloid progenitor 
cell populations in homozygous styx, styx St2–/–, WT, and St2–/– 
mice by flow cytometry, according to Wilson et al. (Supplemen-
tal Figure 3, A and B; ref. 26). Percentages of HSCs (Figure 2, A 
and B) and myeloid progenitors (Figure 2, C and D) were sig-
nificantly increased in the BM of styx mice, compared with WT 
tion, and monocytes from MPN patients may display an increased 
responsiveness to TLR ligands, leading to excessive cytokine pro-
duction (15). Therefore, and although strong causative evidence is 
currently lacking, microbial infections driving sustained inflam-
mation may potentially trigger MPNs.
IL-33 is a recently identified member of the IL-1 family of 
cytokines that binds to a heterodimeric receptor complex consist-
ing of ST2 (IL-1RL1) and IL-1 receptor accessory protein. IL-33 sig-
naling is then further transduced via recruitment of the adapters 
MyD88 and IL-1 receptor–associated kinase 4 (IRAK4), which are 
shared with TLRs. IL-33 is predominantly expressed by endothe-
lial and epithelial cells (16, 17), and it has primarily been impli-
cated in the induction of type-2 immune responses by binding 
to ST2, which is expressed on a variety of cells such as Th2 CD4+ 
T cells, mast cells, and basophils (16). While IL-33 has recently 
emerged as a cytokine with pleiotropic functions in diverse types 
of inflammatory processes — including inflammatory bowel dis-
ease (18) and virus-induced inflammation (19, 20) — its function 
in tumorigenesis is poorly characterized.
Here, we used a mutant allele of the inositol polyphosphate-5-
phosphatase D (Inpp5d, which encodes SHIP, an SRC homology 2 
domain–containing inositol-5-phosphatase) called styx to inves-
tigate the mechanisms underlying spontaneous development of 
MPN-like disease. Since microbial cues can be sufficient to drive 
inflammatory disease in genetically susceptible strains (21, 22), we 
assessed the suppressive effect of a genetic blockade of selected 
inflammatory pathways in the pathogenesis of MPN-like disease in 
Inpp5dstyx/styx mice (herein referred to as styx mice). We identified a 
critical role for MyD88 and IRAK4 in determining the phenotype. 
Our data indicate that microbial-derived signals are dispensable, 
whereas the IL-33/ST2 pathway is non-redundant for initiating 
uncontrolled myelopoiesis in styx mutants. In addition, IL-33 con-
tributes to the development of JAK2V617F-dependent MPNs in mice 
and promotes colony formation of human primary CD34+ MPN 
stem/progenitor cells. IL-33 is also increased in BM biopsies of 
MPN patients. Together, these results reveal a central functional 
involvement of the IL-33/ST2 pathway in MPN pathogenesis.
Results
Development of MPN-like disease is directed by MyD88 but independent 
of microbiota-derived signals. As a model of MPN, we used a Inpp5d 
styx allele that was identified in an N-ethyl-N-nitrosourea (ENU) 
genetic screen. The styx point mutation results in a thymine-to-
adenine transversion in the donor splice site of intron 5 of the Inpp5d 
gene, causing an aberrant transcript lacking exon 5, which in turn 
leads to loss of SHIP protein expression (Supplemental Figure 1, A–D; 
supplemental material available online with this article; doi:10.1172/
JCI77347DS1). SHIP is a negative regulator of the PI3K pathway in 
hematopoietic cells, and its deficiency leads to increased numbers of 
granulocyte-macrophage progenitors (GMPs) in the BM and spleen 
(23). Homozygous styx mice entirely recapitulate the myeloprolifera-
tive-like phenotype of the described Inpp5d KO strains (23, 24), show-
ing hyperproliferative BM, associated splenomegaly, and myeloid cell 
infiltration into several organs, including the spleen, the ileum, and 
particularly the lung (Supplemental Figure 1E). As a consequence, 
styx mutants display a chronic progressive and fatal wasting disease 
with kinetics similar to Inpp5d KO strains (Figure 1A; ref. 23).
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3B and Supplemental Table 1). These findings demonstrate that 
ST2 can be engaged on both stromal and hematopoietic cells and 
that the 2 compartments can compensate for each other to induce 
MPN-like disease in our model.
Importantly, lethally irradiated Il33–/– mice reconstituted with 
styx BM did not develop MPN-like disease (Figure 3A and Supple-
mental Table 1), thereby indicating a non-hematopoietic origin of 
IL-33 for uncontrolled myelopoiesis. Since the BM is the primary 
site of hematopoiesis in adult mice, we investigated whether BM 
stromal cells produce IL-33. IHC analysis showed that IL-33 pro-
tein in BM was expressed at similar levels in styx, styx St2–/–, WT, 
and St2–/– mice. Furthermore, IL-33 expression was restricted to 
few cells — most of which had characteristic histological features 
of endothelial cells (ECs) — lining the BM sinusoids (Supplemen-
tal Figure 3). Thus, although IL-33 is not constitutively expressed 
in ECs along the vascular tree (17), our data demonstrate that it is 
expressed in some BM sinusoidal ECs.
ST2 is expressed on BM stromal and hematopoietic cells, but not 
on myeloid progenitors. To assess how IL-33 produced by radio- 
resistant cells induces MPNs in styx mutants, we analyzed the 
expression pattern of the ST2 receptor on BM cells of styx, styx 
St2–/–, WT, and St2–/– mice. While surface ST2 was not detectable 
on BM HSCs and myeloid progenitors (Supplemental Figure 4), 
we identified a heterogeneous lin+ population of myeloid origin 
cells that expressed ST2 that was CD11bint, Ly6C–, and Ly6G– 
(Figure 4, A and B). Further phenotypic analysis revealed that the 
majority of these cells most likely represented early myeloid cells 
and were CD11bint, FcεRI–, and c-KIT–, while the minority were 
basophils, defined as CD11bint, FcεRI+, c-KIT–, and CD49b+ (Sup-
plemental Figure 5A). These two ST2+ populations accounted for 
5%–6% and 0.7% of total hematopoietic cells in the BM, respec-
tively (data not shown). Importantly, ST2+ BM cells in styx versus 
mice. However, genetic blockade of IL-33/ST2 signaling pre-
vented the aberrant hematopoiesis associated with SHIP defi-
ciency, since percentages of BM HSC and myeloid progenitor 
cell populations were comparable in styx St2–/– mice and WT or 
St2–/– controls (Figure 2, A–D).
In the periphery, effective hematopoiesis with granulocytosis 
and monocytosis were observed in styx but not styx St2–/– mice, as 
measured by complete blood count (CBC) analysis (Figure 2E). 
We next functionally analyzed styx, styx St2–/–, WT, and St2–/– BM 
lineage–negative (lin–) cells for their capacity to form myeloid col-
onies. SHIP-deficient HSCs are known for their increased capac-
ity to form myeloid colonies due to their enhanced sensitivity to 
cytokines (23, 24). Accordingly, styx lin– cells exhibited markedly 
increased colony formation compared with St2–/– and WT controls. 
However, colony numbers were similarly augmented for styx St2–/– 
cells (Figure 2F). This implies that although disruption of IL-33/
ST2 signaling normalizes hematopoietic subsets in styx mice, styx 
St2–/– cells retain an intrinsic hyperproliferative ability.
Taken together, these results reveal that steady-state engage-
ment of the IL-33/ST2 pathway acts as a non-redundant trigger 
for the accumulation of BM HSCs and myeloid progenitors, and 
for the concomitant MPN-like phenotype observed upon SHIP 
loss of function.
Stromal IL-33 engages ST2 signaling on both the radio-resistant 
and the radio-sensitive compartments to induce MPN-like disease. To 
determine the source of IL-33 and the compartment(s) express-
ing ST2 in our model system, we next generated various sets of 
BM chimeric mice. Lethally irradiated St2–/– or control WT hosts 
reconstituted with styx BM developed MPN-like disease with simi-
lar kinetics (Figure 3A). However, genetic abrogation of IL-33/ST2 
signaling on a hematopoietic SHIP-deficient compartment signifi-
cantly delayed, but did not prevent, disease development (Figure 
Figure 1. MyD88/IRAK4-dependent IL-33/ST2 signaling 
promotes MPN-like disease. (A) Survival of single styx 
mutants (n = 142) and of styx mice backcrossed on a 
Myd88- (n = 32), Irak4- (n = 61), and Tnf- (n = 68) deficient 
background. (B) Macroscopic phenotype of 14-week-old styx 
and styx Myd88poc/poc male mice that are Myd88 deficient. 
(C) Survival of styx (n = 142), styx St2–/– (n = 22), styx Il18–/– 
(n = 8), and styx Il1r1–/– (n = 22) mice. Survival curves for styx 
mice in A and C represent the same group of mice. Log-rank 
(Mantel-Cox) test was used, using styx mice as a reference 
group. ***P < 0.001; ****P < 0.0001.
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(23, 24, 28), increased the number of colonies from styx and WT 
lin– BM cells. Moreover, addition of IL-33 to IL-6 and GM-CSF did 
not further modulate the colony-forming ability of lin– cells (Fig-
ure 4D). These results show that IL-33 does not promote colony 
formation of mouse HSCs and myeloid progenitor cells directly, 
and it does not synergize with other known myeloproliferative 
factors. Also, and in agreement with our ST2 expression analysis, 
SHIP-deficiency is not associated with an increased sensitivity of 
HSCs and myeloid progenitors to IL-33, as observed for IL-6 and 
GM-CSF (Figure 4D).
We next performed a coculture assay to dissect how IL-33/ST2 
signaling indirectly supports development of MPN-like disease in 
styx BM. We assessed the contribution of stromal cells, as well as the 
role of the hematopoietic cell population we previously identified 
as constitutively expressing ST2. To this end, we measured colony 
formation by ST2– lin– cells following coculture with IL-33–stimu-
lated primary stromal cells (MACS-purified CD45– BM cells) or after 
supplementation with conditioned medium from IL-33–stimulated, 
ST2+ BM hematopoietic cells. Under these experimental settings, 
we observed an increase in colony formation of styx St2–/– or St2–/– 
lin– BM cells solely in the combined presence of exogenous IL-33 and 
ST2-expressing stromal or hematopoietic responders (Figure 4E).
Hence, we concluded that IL-33 can indirectly support develop-
ment of MPN-like disease in styx mutants via the activation of the 
radio-resistant compartment, as also indicated by our BM chimera 
WT mice did not differ in their relative distribution or their ST2 
expression levels (data not shown).
Since our BM chimera experiments indicated that the radio- 
resistant compartment was also able to promote MPN-like disease 
in an ST2-dependent manner, we correspondingly assessed ST2 
expression on BM stromal cells. We found that ECs (defined as 
CD45–, lin–, CD51–, and CD31+) and mesenchymal stromal cells 
(MSCs; specified as CD45–, lin–, CD31–, CD51+, and CD140a+; ref. 
27) in the BM expressed ST2, although ST2 expression was mar-
ginal on MSCs (Figure 4C and Supplemental Figure 5B).
Together, our data suggest that the BM microenvironment 
contains the minimal requirements to promote myeloproliferative 
disease on a SHIP-deficient background via activation of IL-33/
ST2 signaling. Furthermore, the expression pattern of ST2 indi-
cates that IL-33/ST2 signaling likely has an indirect effect on styx 
HSCs and myeloid progenitors.
IL-33 acts indirectly on HSCs and myeloid progenitors. In order 
to determine a potential indirect mode of action of IL-33/ST2 
signaling in HSCs and myeloid progenitor cells, we used mag-
netic cell separation to purify lin– cells from styx or WT BM and 
assessed their capacity to form colonies in the presence or absence 
of IL-33 (Figure 4D). IL-33 alone did not affect colony formation 
of lin– BM cells. However, stimulation with IL-6 and/or GM-CSF, 
factors known to promote myeloproliferation and contribute to the 
dysregulated hematopoiesis characteristic of SHIP-deficient mice 
Figure 2. IL-33/ST2 signaling alters BM HSC and myeloid progenitor cell populations, promoting systemic myeloproliferation. Flow cytometric analysis of 
lin– BM cells show different frequencies of (A) long-term HSC (LT-HSC) and (B) short-term HSC (ST-HSC), (C) common myeloid progenitors (CMP) and (D) GMPs 
in the indicated mouse strains. (E) CBC analysis of myeloid cells. (F) CFU of the indicated lin– BM cells after 7 days of culture in the presence of IL-3, FLT3-ligand, 
and SCF. Data are mean ± SEM. Pooled data from 3 (A and D) or 2 (E and F) independent experiments are represented (n = 5–10 mice per group). (A–F) One-way 
ANOVA with Bonferroni post hoc test was used; only statistically significant data are presented. *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
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tants of both CD45– and CD45+ cell fractions (Figure 5). IL-5 
was only secreted by CD45+ hematopoietic cells. Engagement 
of IL-33/ST2 signaling was required, as specific cytokine secre-
tion was abrogated in the absence of ST2 (Figure 5). Therefore, 
we deduced that the BM microenvironment is able to produce 
growth factors in response to secreted IL-33 to provoke uncon-
trolled myeloproliferation in styx mice.
SHIP-deficient myeloid cells display a higher responsiveness 
to cytokines, such as GM-CSF and IL-3, that leads to a reduced 
susceptibility to apoptotic stimuli (23, 24). Consequently, we next 
evaluated whether IL-33/ST2 signaling may affect the viability of 
styx BM cells. We found that ex vivo CD11b+ BM styx St2–/– cells 
cultured for short term (6 hours) without cytokine supplemen-
tation showed survival rates similar to control cells but reduced 
compared with ST2-proficient styx cells (Supplemental Figure 
7A). Correspondingly, in vitro stimulation with IL-33 promoted 
the survival of styx but not styx St2–/– CD11b+ BM cells (Supple-
mental Figure 7B).
In summary, these data support the notion that IL-33 is an 
important trigger for the production of effector cytokines by the 
stromal and hematopoietic compartments. These cytokines, in 
turn, promote enhanced survival and proliferation of myeloid 
cells, eventually resulting in MPN-like disease in styx mutants.
Stromal IL-33 supports the development of JAK2V617F-dependent 
MPNs in vivo. To assess the contribution of IL-33/ST2 signaling to 
dysregulated myelopoiesis in a different model of MPN, we adop-
tively transferred BM cells transgenic for the JAK2V617F mutation 
(30) into Il33–/– recipient mice. In these chimeras, we found a lower 
percentage of JAK2V617F+ GMPs in the BM and a reduced frequency 
experiments (Figure 3). Our results also suggest that the ST2-express-
ing hematopoietic population in the BM is able to sustain myelopro-
liferation, likely via the secretion of soluble factors. In addition, the 
contribution of ST2+ hematopoietic cells to development of myelo-
proliferation in styx mice appears to be superior to the one provided 
by ST2+ stromal cells, in line with our findings from the BM chimeras.
IL-33 induces cytokine and growth-factor secretion by BM cells. 
Increased levels of several growth and survival factors in the 
peripheral blood have been proposed to contribute to the dys-
regulated hematopoiesis observed in SHIP-deficient mice (29). 
Accordingly, analysis of the sera of 40-day-old styx mice that were 
healthy in appearance showed that the levels of cytokines critical in 
supporting myelopoiesis — including G-CSF, IL-6, and to a lesser 
extent GM-CSF, M-CSF, IL-3, and IL-5 — were already elevated 
in several mutants at this age (Supplemental Figure 6, A–F). Con-
versely, the same cytokines were present at low concentrations in 
age-matched styx St2–/–, WT, or St2–/– mice. Although we previously 
identified TNF as a partial mediator of MPN-like disease, it was not 
elevated in the serum of young styx mice (Figure 1A and Supple-
mental Figure 6G). However, serum IL-33 levels were significantly 
augmented in the mutants (Supplemental Figure 6H).
SHIP has been suggested to regulate the production of solu-
ble factors produced by the BM niche (29). To assess the ability 
of the BM microenvironment to secrete cytokines and growth 
factors in response to IL-33 and thus promote myelopoiesis, we 
isolated BM cells from styx and WT mice, and we MACS-puri-
fied them into CD45– non-hematopoietic and CD45+ hemato-
poietic cell fractions. Ex vivo stimulation with IL-33 increased 
the levels of G-CSF, GM-CSF, IL-3, and IL-6 in the superna-
Figure 3. Stromal cell–derived IL-33 engages ST2 signaling on both the stromal and the hematopoietic compartment to induce MPN-like disease. (A) 
Contribution of IL-33 and IL-33/ST2 signaling in radio-resistant cells. (B) Contribution of IL-33/ST2 signaling in radio-sensitive cells. Survival curves and 
disease activity index are shown for the indicated groups of BM chimeric mice. Pooled data from 2 independent experiments are represented each for (A) 
styx→WT (n = 14), styx→St2–/– (n = 8), styx→Il33–/– (n = 9), and (B) styx→WT (n = 9), styx St2–/–→styx St2–/– (n = 10), and styx St2–/–→WT (n = 10). Log-rank 
(Mantel-Cox) test was used. † indicates euthanasia of animals. ***P < 0.001; ****P < 0.0001.
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Figure 4. ST2 expression and function in the BM. (A) ST2 expres-
sion on hematopoietic BM cells is restricted to committed myeloid 
cells (CD11bint, Ly6G–, and Ly6C–). Representative histogram of one 
styx and one WT mouse is shown. (B) Cytospin of FACS-purified 
BM CD11bint, Ly6G–, Ly6C–, ST2+ cells showing phenotypical hetero-
geneity (scale bars: 20 μm). (C) ST2 expression on BM endothelial 
cells (defined as CD45–, lin–, CD51–, and CD31+). (D) Lin– BM cells 
from styx and WT mice were cultured in methylcellulose with the 
indicated cytokines. Colony numbers were assessed after 7 days. 
(E) BM primary stromal cells were grown in vitro (46). MACS-puri-
fied CD45– cells from these cultures were stimulated with IL-33 for 
24 hours, before addition of lin– cells for coculture. Alternatively, 
lin– cells were supplemented with conditioned medium from 
FACS-purified CD11bint, Ly6G–, and Ly6C– cells previously stimu-
lated with IL-33 for 24 hours. Then, styx St2–/– or St2–/– lin– cells 
incubated for 48 hours under these respective conditions were 
cultured in methylcellulose for 7 days, and colony formation was 
assessed. Conditions for culture (± IL-33) and genotypes of stromal 
or hematopoietic stimulation responders (+: styx St2+/+; -: styx 
St2–/–) are indicated. Data are mean ± SEM and are representative 
of (A) n = 8 mice per group; (B) n = 2 mice per group; (C) pooled 
cells from 4 WT mice, repeated twice; (D) pooled data of 2 experi-
ments, n = 6 mice per group; and (E) 1 experiment where each data 
point represents 2 pooled mice (n = 6 mice per group). Stromal and 
hematopoietic responders were pooled from 5 donors. (D and E) 
One-way ANOVA with Bonferroni post hoc test was used.  
*P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
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of blood neutrophils (defined as CD11b+ and Ly6G+) compared 
with control mice expressing IL-33 in the stroma (Figure 6, A and 
B). IL-33–deficiency in the radio-resistant compartment also cor-
related with delayed expansion of several hematopoietic lineages 
from donor JAK2V617F+ BM cells (Figure 6C). Taken together, these 
data suggest that stromal cell–derived IL-33 supports the develop-
ment of JAK2V617F-dependent MPNs in vivo.
Increased levels of IL-33 protein in the BM of MPN patients. To 
address the general relevance of the findings from our mouse 
models of MPN, we assessed the presence of IL-33 in the BM of 
MPN patients. IL-33 was also expressed in human BM biopsies 
and was localized in the nucleus of cells that were mainly but not 
solely endothelial, based on their histomorphological presen-
tation and expression of CD34 (Figure 7, A and B). Automated 
quantification of cells displaying nuclear IL-33 expression indi-
cated that MPN patients newly diagnosed with ET, PMF, and PV, 
but not CML, display a higher percentage of IL-33+ BM cells com-
pared with controls (Figure 7C). This increase seemed specific 
to BCR-ABL1–negative MPN patients, as it was not detected in 
other types of chronic or acute leukemia affecting the myeloid or 
lymphoid lineages (Supplemental Figure 8A). Hence, these data 
suggest that the IL-33/ST2 pathway may also play a role in the 
pathogenesis of human MPNs.
MPN cell lines and CD34+ stem/progenitor cells from MPN 
patients directly respond to IL-33. The IHC findings from patient 
BM biopsies raised the question as to whether IL-33 also exerts 
a proproliferative effect on human MPN cells. In particular, 
the increase in IL-33 protein expression in BCR-ABL1–negative 
MPNs prompted us to examine the effect of IL-33 on human 
JAK2V617F+ cells. In vitro experiments showed that IL-33 pro-
moted the upregulation of CSF2 (GMCSF) and IL6 transcripts in 
several JAK2V617F+ cell lines (Figure 8A). These cell lines consti-
tutively expressed ST2 on the surface (Supplemental Figure 8B). 
IL-33 did not stimulate the growth of MPN cell lines; however, 
it improved their survival (Figure 8B). Human BCR-ABL1+ CML 
cell lines expressed ST2 at various intensities, and they also 
upregulated the transcription of growth factors when stimulated 
with IL-33 (Supplemental Figure 8, C and D). However, IL-33 did 
not influence the proliferation or the survival of CML cell lines 
(Supplemental Figure 8E). These results suggest that JAK2V617F+ 
cells are more sensitive to the effects of IL-33/ST2 signaling 
compared with BCR-ABL1+ CML cells.
Primary human CD34+ hematopoietic stem/progenitor cells 
(HSPCs) express ST2 receptor and secrete cytokines and chemok-
ines when stimulated with IL-33 (31). We detected increased ST2 
expression on CD34+ stem/progenitor cells from BCR-ABL1–nega-
tive MPN patients (Figure 8, C and D). In agreement with our data 
from cell lines, GMCSF expression was significantly upregulated 
in circulating CD34+ stem/progenitor cells from CML patients 
and CD34+ HSPCs from controls following IL-33–mediated stim-
ulation (Supplemental Figure 8F). Furthermore, IL-33 promoted 
colony formation of CD34+ MPN stem/progenitor cells but not of 
CD34+ control HSPCs (Figure 8E).
Collectively, these observations extend our in vivo data in 
SHIP-deficient mice and substantiate their relevance to human 
MPNs. Our findings also point toward differences as to how the 
IL-33/ST2 pathway may exert an effect on MPN progenitors — 
either via the intermediate of differentiated cells that are ST2+ in 
the mouse model or directly on ST2-expressing CD34+ stem/pro-
genitor cells in MPN patients (Figure 9).
Figure 5. IL-33 is a potent inducer of cytokines and growth factors promoting myelopoiesis. BM cells from the indicated strains were MACS-puri-
fied into CD45+ (enriched for hematopoietic) and CD45– (enriched for stromal) cells and cultured ± IL-33. After 24 hours, supernatant was collected, 
and concentrations of (A) G-CSF, (B) GM-CSF, (C) IL-3, (D) IL-5, and (E) IL-6 were measured by LASER Bead Technology. Each condition represents 
the value measured from pooled cells from 7 (styx) or 10 (styx St2–/–, WT, and St2–/–) mice. A comparable trend was found after 12 hours of culture ± 
IL-33 (not depicted).
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lung and intestine — organs that contain relatively high numbers 
of IL-33–expressing cells (Supplemental Figure 9; ref. 17). This 
immunopathology likely leads to rising concentrations of IL-33 in 
the serum, as detected in styx mutants. The evidence that altered 
hematopoiesis develops spontaneously in our model is still recon-
cilable with our initial hypothesis proposing that external stimuli 
may promote MPN development. IL-33 released during infection 
with pathogens (19, 20) may indeed further precipitate uncon-
trolled myeloproliferation. Also, opportunistic infections may be 
the cause of the accelerated disease observed in styx mice deficient 
in Tlr4, Unc93b1, or Il18 (Figure 1, A and B, Supplemental Figure 
2A, and Figure 1C). Accordingly, the irradiation-induced increase 
in proinflammatory cytokines such as IL-6 and G-CSF, but also 
IL-33 (35, 36), likely accounts for the accelerated disease kinetics 
observed in chimeric mice reconstituted with styx BM compared 
with nonmanipulated styx mutants (Figures 1 and 3). Irradia-
tion-induced systemic inflammation may also mask the relative 
contribution of radio-resistant cells to MPN-like disease in our 
model. This may explain why the styx→WT and styx→St2–/– sets 
of chimeras develop MPN-like disease with similar kinetics (Fig-
ure 3); however, our data show that BM stromal cells can engage 
ST2, for example to promote colony formation in vitro (Figure 4E). 
Increased availability of IL-33 in the BM may similarly support dis-
ease pathogenesis in BCR-ABL1–negative MPN patients.
Critically, we observed a different ST2 expression pattern in 
mice compared with humans. In the BM of styx and WT mice, 
ST2 expression was restricted to non-hematopoietic stromal and 
committed hematopoietic cells. ST2 protein was undetectable 
on murine HSCs and myeloid progenitors, and addition of IL-33 
Discussion
IL-33 has hitherto essentially been described as a nuclear alarmin 
that is released following necrotic cell death or under conditions of 
cellular stress. On the other hand, IL-33 undergoes caspase-medi-
ated inactivation during apoptosis (reviewed in ref. 16). Inflamma-
tory cues such as IFNγ and IL-4, as well as microbial products such 
as LPS, strongly induce expression of endogenous IL-33 (17, 32). 
Here we present evidence that IL-33 signaling can also be engaged 
in vivo to drive tumorigenesis and immunopathology under ster-
ile, steady-state conditions in mice.
Although we can merely speculate about the initial source 
of IL-33 to induce MPN-like disease in styx mice, the BM stroma 
emerges as a valid local provider of this cytokine, since IL-33 is 
expressed in the niche. Exposure to fungus allergens leads to the 
ATP-dependent release of IL-33 in the airways of challenged mice 
(33). However, no mechanism has been proposed so far as to whether 
and how active IL-33 may be released or secreted from healthy, non- 
stressed cells in vivo. Nevertheless, low amounts of the active form 
of IL-33 can be detected in the serum of healthy human donors (34) 
and in 2 of the 8 naive WT mice we tested. Serum IL-33 can likely 
transit through the BM. Notably, St2–/– mice displayed higher lev-
els of serum IL-33 than WT controls (122 ± 42 versus 3 ± 1 pg/ml, 
P < 0.01). This suggests that IL-33 is released and circulates even 
under steady-state conditions and that ST2 regulates its availability. 
Thus, it is conceivable that steady-state levels of IL-33 may trigger 
a self-amplifying inflammatory milieu favorable to tumor develop-
ment in genetically susceptible hosts.
Upon disease progression in SHIP-deficient animals, infil-
trating immune cells progressively cause tissue damage to the 
Figure 6. Stromal cell–derived IL-33 supports the development of JAK2V617F-dependent MPNs in vivo. BM cells from Scl-Cre JAK2V617F transgenic donor 
mice were injected into lethally irradiated Il33–/– or WT recipient mice. After 7 weeks, (A) percentage of GMPs in the BM and (B) frequency of neutrophils in 
the blood were assessed. (C) Alternatively, indicated blood parameters were evaluated every other week by CBC, starting 3 weeks after reconstitution. n = 5 
mice per group. For C, 1 representative of 2 independent experiments is shown. (A and B) Standard Student’s t test, and (C) 2-way ANOVA with Bonferroni 
post hoc test were used. *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
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IL-33 has a dual function, both as an inhibitor of transcription 
when residing in the nucleus (39) or as a proinflammatory cytok-
ine upon release (16). Our results suggest that in its extracellular 
function and through ST2 binding, IL-33 promotes dysregulated 
hematopoiesis in the styx and transgenic JAK2V617F models, as well 
as cytokine production in stimulated MPN cells. Interestingly, 
plasma levels of IL-33 are not altered in CML patients (37) and are 
even reduced in patients suffering from PV or ET (34). Although 
availability of secreted IL-33 in the niche has yet to be demon-
strated, we clearly show that nuclear IL-33 is expressed to a greater 
extent in the BM of newly diagnosed BCR-ABL1–negative MPN 
patients compared with controls. Since MPN stem/progenitor 
cells display hypersensitivity to cytokines and growth factors, sim-
ilarly to SHIP-deficient HSCs and myeloid progenitor cells (2, 23), 
it is conceivable that even low amounts of secreted IL-33 within 
the niche may suffice to initiate ST2-dependent inflammation that 
supports MPNs.
While the soluble form of ST2 appears to be a predictive marker 
for clinical stage and outcome in CML (37), no such data exist on the 
role for IL-33/ST2 signaling in the progression of BCR-ABL1–nega-
tive MPNs. In particular, its potential contribution to the progres-
sion to end-stage myelofibrosis is unclear. IL-33 has a known direct 
proangiogenic effect on ECs (40), and increased microvessel den-
to these cells did not modulate their capacity to form colonies. 
However, human CD34+ stem/progenitor cells from controls and 
MPN patients were able to engage IL-33/ST2 signaling to produce 
growth factors and proinflammatory cytokines, an observation 
previously made by others (31). Also, a recent study reported that 
ST2 is upregulated on CD34+ stem/progenitor cells from CML 
patients (37). Therefore, it remains to be addressed whether these 
differences in ST2 expression patterns rely on species-dependent 
divergences and whether ST2 can be also engaged on human BM 
stromal cells. This is relevant because humoral factors secreted by 
BM stromal cells may also support MPN pathogenesis by impair-
ing compound-mediated JAK2 inhibition (11).
Our data indicate an indirect effect of the IL-33/ST2 pathway 
for the development of MPN-like disease in the styx model, via the 
production of soluble factors. Several of the cytokines released by 
ST2+ BM cells have previously been shown to support dysregulated 
myeloproliferation in Inpp5d KO mice (23) and also in other murine 
models of MPN (38). These IL-33–induced cytokines likely also 
promoted the aberrant expansion of JAK2V617F+ hematopoietic cells 
in BM recipient mice. However, IL-33–induced cytokines appear 
to be redundant for MPN development. For instance, blockade of 
IL-6 signaling only partially corrects the aberrant hematopoiesis 
in SHIP-deficient (28) or transgenic BCR-ABL1 mice (4).
Figure 7. Increased levels of IL-33 protein in trephine biopsies of MPN 
patients. IHC for (A) IL-33 (brown) (scale bar: 100 μm) and for (B) IL-33 
(brown) and CD34 (red) in normal and MPN BM (scale bar: 20 μm). (C) 
Percentage of IL-33–positive nuclei in BM of controls (n = 6) and of 
patients newly diagnosed with the indicated hematopoietic malignan-
cies. CML (n = 11), ET (n = 12), PV (n = 13), and PMF (n = 9). Data are mean 
± SEM. Kruskal-Wallis with Dunn’s post hoc test was used; control 
biopsies were compared with all other groups. *P < 0.05; **P < 0.01.
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of Bern, Switzerland; control samples were obtained from non-leukemic 
individuals showing minimal reactive changes. All CML patients were 
positive for the BCR-ABL1 transcript.
Animals. All strains used were on a C57BL/6J background. 
C57BL/6J mice bred at The Scripps Research Institute (TSRI) were 
injected with ENU, as described (42). The Inpp5dstyx/styx (styx mice), 
Myd88poc, Irak4otiose, Tlr2languid, Tlr4lps3, TnfPanR1, and Unc93b13d strains 
are described at the Southwestern Medical Center Mutagenetix data-
base (http://mutagenetix.utsouthwestern.edu). B6.129S7- Il1r1tm1Imx/J, 
B6.129P2-Il18tm1Aki/J, and B6.SJL-Ptprca Pep3b/BoyJ mice were 
obtained from The Jackson Laboratory. Il33–/– mice (43) were obtained 
through the RIKEN Center for Developmental Biology (Acc. No. 
CDB0631K; http://www.cdb.riken.jp/arg/mutant%20mice%20list.
html). Il1rl1–/– (St2–/–) mice have been described (44). The styx mice 
were rederived to germ-free status by 2-cell embryo transfer and were 
maintained in flexible film isolators in the Clean Mouse Facility, Uni-
versity of Bern, Switzerland. BM cells from transgenic JAK2V617F (Scl-
Cre FF1; ref. 45) mice were provided by Radek C. Skoda (University 
Hospital Basel, Basel, Switzerland). For survival analyses, data were 
collected during the entire course of the study and pooled for graphic 
representation. Unless indicated in the corresponding figure, animals 
used in this study were 6–12 weeks old and age/sex-matched.
sity has been associated with fibrosis in JAK2V617F mutation-bearing 
MPN patients (41). Furthermore, abnormal expression and activity 
of a number of proinflammatory cytokines are linked to myelofibro-
sis (10), and our results indicate that IL-33 promotes the secretion of 
various cytokines in the BM microenvironment. Therefore, it may 
be relevant in the future to address whether therapeutic blockade of 
the IL-33/ST2 axis may prevent myelofibrosis or halt its progression.
In summary, our data provide evidence for a role of IL-33/
ST2 signaling for dysregulated hematopoiesis in mouse models 
of MPN. They also indicate that IL-33 expression is specifically 
increased in the BM of BCR-ABL1–negative MPN patients. Our 
results warrant further investigation on the contribution of the 
IL-33/ST2 axis to disease pathogenesis in MPN patients.
Methods
Patients. PBMCs from CML or JAK2V617F-positive patients at diagnosis — 
or from donors who underwent peripheral blood stem and progenitor 
cell mobilization and collection for reasons other than hematological 
neoplasms — were obtained from the Department of Hematology of the 
University Hospitals of Bern and Zurich, Switzerland, and were enriched 
for CD34+ stem/progenitor cells by MACS. Samples from BM biopsies 
were retrieved from the archives of the Institute of Pathology, University 
Figure 8. IL-33/ST2 signaling promotes MPN development. (A) Indicated JAK2V617F+ cell lines were incubated for 24 hours ± IL-33, and expression 
levels were measured for the transcripts of the indicated genes. Mean expression levels of technical duplicates are represented as fold induction 
and have been normalized to conditions without IL-33. (B) The MPN cell lines SET-2 and HEL were cultured ± IL-33, and percentage of live cells 
(annexin V– DAPI–) was assessed at the indicated time points. Results show means ± SEM. (C) Relative median fluorescence intensity (MFI) of 
ST2 expression on blood CD34+ stem/progenitor cells from MPNs (PMF [n = 3], PV [n = 5], and after ET/PV myelofibrosis [n = 3]) and control (n = 5) 
donors. (D) Representative histograms showing ST2 expression on blood CD34+ stem/progenitor cells from the indicated donors. (E) Colony forma-
tion assay (CFA) from MACS-purified blood CD34+ stem/progenitor cells from controls and MPN patients cultured in standard CFC medium ± IL-33 
for 2 weeks. Data are mean ± SEM and show fold changes in colony numbers after normalization to conditions without IL-33. Healthy (n = 5) and 10 
MPN donors were used. (A) One representative of 2 independent experiments, and (B) pooled values from 3 individual experiments are shown.  
(C and D) Pooled data from 2 independent experiments are shown. (B) Standard Student’s t test, (C) Standard Student’s t test with Welch’s  
correction, and (D) Wilcoxon signed-rank test were used. *P < 0.05; **P < 0.01.
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Colony formation assay. Purified, lin– murine BM cells were cultured 
at a starting density of 2 × 103 to 5 × 103 for 7 days in MethoCult-based 
medium (StemCell Technologies Inc.) supplemented with 15% FCS, 100 
U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 100 μM 
2-mercaptoethanol, and 20% BIT (50 mg/ml BSA in IMDM, 1.44 U/ml 
rh-insulin, 250 ng/ml human holo transferrin). The following cytokines 
were always included: 50 ng/ml rm SCF, 10 ng/ml, 50 ng/ml rm Flt3- 
ligand, and 10 ng/ml rm IL-3. The following cytokines were added when 
specified: 10 ng/ml rh IL-6, 10 ng/ml, rm GM-CSF, and 100 ng/ml rm 
IL-33 (all from ProSpec). Colonies were counted using a DMIL inverted 
microscope (Leica Microsystems) mounted with an Intensilight C-HGFI 
unit (Nikon). Alternatively, 1 × 103 primary blood CD34+ stem/progeni-
tor cells from MPN patients or healthy donors were plated in MethoCult 
H4435 Enriched medium (StemCell Technologies Inc.) with or without 
100 ng/ml rh IL-33 (ProSpec). Colonies were counted after 14 days.
Flow cytometry. BM cells were resuspended and filtered through 
70 μm cell strainers (Falcon Technologies BD) to obtain single-cell 
suspensions. Following rbc lysis, FcR blockade, and lineage deple-
tion, HSCs and myeloid progenitors were stained as described pre-
viously (26), using the antibodies indicated in Supplemental Table 
2. Live/dead cell discrimination was performed using DAPI (Bio-
Legend) and annexin V (BioLegend). The gating strategy used to dis-
criminate HSC and myeloid progenitor cell populations is shown in 
Supplemental Figure 3, A and B.
Blood-derived, MACS-purified CD34+ human stem/progenitor 
cells were carefully thawed in HBSS containing 10% human serum. 
After centrifugation, cells were resuspended in IMDM and analyzed 
for colony formation or ST2 surface expression. The gating strategy 
used to assess ST2 expression on primary human CD34+ stem/progen-
itor cells is shown in Supplemental Figure 10.
Figure 9. Models for the development of MPN in the BM microenvironment. (A) Model for SHIP-deficient mice. Stromal cell–derived IL-33 is released 
under stress or steady-state conditions through a pathway that is yet to be determined. IL-33 engages its receptor ST2 on stromal cells or, preferen-
tially, on a committed population of myeloid cells. Signal transduction via the ST2→MyD88→IRAK4 axis promotes the secretion of several cytokines 
and growth factors promoting myoproliferation — among others GM-CSF and IL-6 — that bind to their respective receptors and activate the JAK2/STAT5 
pathway (49). SHIP is a negative regulator in this process, and impaired SHIP-mediated inhibition results in MPN-like disease. (B) IL-33 released by stromal 
cells in the human BM engages ST2 receptor on CD34+ HSPCs. Activation of cell signaling downstream of ST2 leads to the production of autocrine cyto-
kines and growth factors that support proliferation.
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Quantitative PCR assay. Mouse primary BM cells were MACS- 
purified with a murine CD45 micro-bead assay (Miltenyi Biotec) 
according to the manufacturer’s protocol. RNA from human cell lines or 
primary MACS-purified CD34+ stem/progenitor cells from donors was 
purified using TRI-reagent (Sigma-Aldrich). RNA was transcribed into 
cDNA using M-MLV reverse transcriptase (Promega). FastStart SYBR 
Green Master (Roche Diagnostics) was used to detect the target genes 
GCSF, GMCSF, IL6, and GAPDH (QIAGEN). All reactions were run in a 
StepOnePlus Real-Time PCR System (Invitrogen). Expression levels of 
genes were normalized to GAPDH mRNA, and IL-33–stimulated versus 
unstimulated groups were compared applying the 2–ΔΔCT method.
Human MPN cell lines. The human CML cell lines JURL-MK1, 
KU812, LAMA-84, and NALM-1 were provided by Patrick Ziegler 
(University Hospital Aachen, Aachen, Germany). The human JAK2V617F 
cells lines HEL 92.1.7 (HEL), SET-2, and UKE-1 were provided by 
Radek C. Skoda (University Hospital Basel, Basel, Switzerland).
Cytokine measurement. MACS-purified primary cells were stimu-
lated with 100 ng/ml rm IL-33 for 24 hours ex vivo. Cells were centri-
fuged for 5 minutes at 500g, and supernatant was removed. Cell cul-
ture supernatant and serum cytokines were analyzed by Multiplexing 
LASER Bead Technology (Eve Technologies).
Statistics. Two-tailed standard Student’s t test with or without 
Welch’s correction and Wilcoxon signed-rank tests were used as 
indicated for single comparisons. For datasets where multiple com-
parisons were performed, one-way ANOVA was performed with Bon-
ferroni post hoc test. For survival curves, log-rank (Mantel-Cox) test 
was used. For all statistical analyses, P values of less than 0.05 were 
considered significant.
Study approval. Patients and donors gave written informed con-
sent, and the analyses of samples were approved by the cantonal Eth-
ics Committee from Bern (Ethics Committee Bern, Bern, Switzerland) 
and Zurich (Ethics Committee Zurich, Zurich, Switzerland).
All animal experiments were performed in accordance with insti-
tutional and federal regulations governing animal care and use ,and 
were approved by TSRI Institutional Animal Care and Use Committee 
(La Jolla, California, USA) and the Cantonal Veterinary Office of Bern 
(Bern, Switzerland).
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Coculture experiment. Regarding preparation of BM stromal 
responders, BM stromal cell (BMSC) cultures were set up from epi-
physes from 5 mice per group, as described previously (46). CD45– 
BMSCs were MACS-purified after 3 weeks of expansion, and ST2 
expression was confirmed by flow cytometry (data not shown). Then, 
5 × 104 purified BMSC were stimulated with 100 ng/ml rm IL-33 for 
24 hours. In preparation of supernatant from BM hematopoietic 
responders, 5 × 104 FACS-purified CD11bint Ly6G– Ly6C– hemato-
poietic BM cells pooled from 5 mice per group were stimulated with 
our without 100 ng/ml rm IL-33. Supernatant was collected after 
24 hours and stored frozen. Next, 5 × 105 lin– MACS-purified BM 
cells pooled from 6 mice per group were added to IL-33–stimulated 
BMSCs for coculture or supplemented with supernatant from IL-33–
stimulated hematopoietic cells. After 48 hours of culture, 5 × 103 lin– 
cells were seeded for colony formation assay as described above.
CBC. Blood was obtained through retro orbital bleeding of anes-
thetized mice and collected in Microvette (Sarstedt) tubes. CBC was 
assessed on a Vet abcTM Animal Blood Counter (Scil Animal Care 
Company GmbH).
Chimeric experiments. Mice were irradiated twice with an individual 
dose of 650 cGy with 4 hours recovery time between. Mice were then 
adoptively transferred i.v. with 1 × 107 cells from whole BM of donor mice.
Scoring of Disease Activity Index (DAI). DAI was determined twice 
every week using a score index approved by the local authorities and 
based on previous reports (47, 48). Score was determined according 
to specific criteria. Behavior scores were as follows: apathy (2.8); hid-
ing, not active, aggressive upon touch (1.8); hiding, calm, active upon 
touch (0.5); and active, attentive (0). Breathing scores were as follows: 
impaired, heavy breathing (2.8); and normal breathing (0). Body con-
ditioning scores were as follows: emaciated (1.8); under-conditioned 
(0.5); and well-conditioned (0). Exercise and posture scores were as 
follows: paralysis (2.8); bent posture, strong bristling of hairs, motoric 
disorder (1.8); uncoordinated upon touch, bent posture, mild bristling 
of hairs (0.5); and normal (0).
Histology and IHC. Mouse and human tissues were fixed in 4% 
formaldehyde for 24 hours prior to dehydration and paraffin embed-
ding. Sections were deparaffinized and stained with hematoxylin and 
eosin (H&E) or PAP under standard conditions. Antigen retrieval for 
IHC was performed with treatment in a 1 mM Tris/1 mM EDTA pH 
9.0 solution for 18 minutes or in Bond Epitope Retrieval Solution 2 
(Leica Biosystems) for 30 min at 95°C, for murine (IL-33) or human tis-
sue (IL-33 and CD34), respectively. After an endogenous peroxidase 
block, primary goat anti-mouse IL-33, goat anti-human IL-33 (both 
from R&D Systems), and mouse anti-human CD34 (Dako) antibod-
ies were used at a dilution of 1:100, 1:400, and 1:200, respectively. A 
secondary rabbit anti-goat antibody (Dako) or rabbit anti-rat antibody 
(Leica Biosystems) (1:100), followed by a tertiary horseradish peroxi-
dase–linked (HRP-linked) anti-rabbit antibody (Dako or Leica Biosys-
tems), was used undiluted to detect positive cells.
IHC of tissues from Il33–/– mice was performed to exclude unspe-
cific staining of the murine IL-33 antibody used in this study. As 
another negative control for antibody specificity, we incubated the 
goat anti-mouse IL-33 antibody with rm IL-33 prior to the staining of 
tissue from Il33+/+ mice. We also stained tissue from Il33+/+ mice with 
a goat anti-rabbit isotype control antibody (Dako). Slides were quanti-
fied with Aperio Group LLC. Settings used for analysis were adjusted 
and controlled by a board certified pathologist in a blinded fashion.
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